Search results
Results from the WOW.Com Content Network
PEGylation (or pegylation) is the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol (PEG, in pharmacy called macrogol) polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, which is then described as PEGylated.
Pegylated interferon alfa-2a is in the alpha interferon family of medications. [3] It is pegylated to protect the molecule from breakdown. [6] Pegylated interferon alfa-2a was approved for medical use in the United States in 2002. [3] It is on the World Health Organization's List of Essential Medicines. [7]
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin), it is no longer recommended due to poor efficacy and adverse side-effects. [4] Subcutaneous injection is the preferred delivery method. [3]
It can be useful to improve bioavailability and extend the half-life of various therapeutic proteins. [2] [1] [3] Examples of glycopegylated molecules include pegozafermin [4] and recombinant factor IX. [5]
Pegipanermin (USAN Tooltip United States Adopted Name; developmental code names and proposed brand names DN-TNF, INB-03, LIVNate, Quellor XENP345, XPro1595) is a tumor necrosis factor α (TNFα) inhibitor which is under development for the treatment of Alzheimer's disease, mild cognitive impairment, major depressive disorder, and other indications.
Pegylated interferon-alpha-2b; Pegylated interferon beta-1a [2] In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body. [3] They are used to treat both hepatitis B, [4] hepatitis C [1] and multiple sclerosis. [2] Pegylated interferon is contraindicated in patients with hyperbilirubinaemia. [citation ...
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment . The company was founded in 1998 and went public in 2004.
Pegaptanib is a pegylated anti-vascular endothelial growth factor (VEGF) aptamer, a single strand of nucleic acid that binds with specificity to a particular target. . Pegaptanib specifically binds to the 165 isoform of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary ...